Last reviewed 2026-05-19 · How we verify

TG103,QW

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Phase 2 active Small molecule ✓ Verified May 2026

TG103,QW is a Small molecule drug developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. It is currently in Phase 2 development. Also known as: TG103 injection, subcutaneous injection,QW.

TG103,QW is a small molecule tubulin inhibitor used in a Phase Ⅱ trial for Type 2 Diabetes Mellitus. The trial compares the efficacy of TG103,QW to placebo and dulaglutide in patients with Type 2 Diabetes Mellitus.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TG103,QW
Also known as	TG103 injection, subcutaneous injection,QW
Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of TG103 Injection in Type 2 Diabetes Subjects (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TG103,QW CI brief — competitive landscape report
TG103,QW updates RSS · CI watch RSS
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about TG103,QW

What is TG103,QW?

TG103,QW is a Small molecule drug developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd..

Who makes TG103,QW?

TG103,QW is developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (see full CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. pipeline at /company/cspc-baike-shandong-biopharmaceutical-co-ltd).

Is TG103,QW also known as anything else?

TG103,QW is also known as TG103 injection, subcutaneous injection,QW.

What development phase is TG103,QW in?

TG103,QW is in Phase 2.

Manufacturer: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. — full pipeline
Also known as: TG103 injection, subcutaneous injection,QW

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing